

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1.-8. (Canceled)

9. (Currently Amended) A method for producing human Tr1-like regulatory cells, which method comprises the steps of:

- (a) ~~separating CD4⁺CD25⁺ T cells from CD4⁺CD25⁻ T cells; and~~
- (b) anergizing CD4⁺ CD25⁻ T cells by contacting the CD4⁺ CD25⁻ T cells with ~~CD4⁺CD25⁻ T cells~~ CD4⁺CD25⁺ T cells *ex vivo* or *in vivo* to yield human Tr1-like regulatory cells; and
- (b) separating human Tr1-like regulatory cells from the CD4⁺CD25⁺ T cells.

10. (Canceled)

11. (Currently Amended) The method of claim 9, wherein step ~~[(b)]~~ (a) of said method comprises coculturing the CD4⁺ CD25⁻ T cells with CD4⁺ CD25⁺ T cells.

12.-28. (Canceled)

29. (Previously Presented) The method of claim 9, wherein said Tr1-like regulatory cells produce IL-10.

30. (Previously Presented) The method of claim 29, wherein said Tr1-like regulatory cells suppress the proliferation of syngeneic CD4⁺ T cells.

31.-34. (Canceled)

35. (New) The method of claim 9, which comprises anergizing CD4⁺ CD25⁻ T cells by contacting the CD4⁺ CD25⁻ T cells with CD4⁺ CD25⁺ T cells *ex vivo*.

36. (New) The method of claim 9, which comprises anergizing CD4⁺ CD25⁻ T cells by contacting the CD4⁺ CD25⁻ T cells with CD4⁺ CD25⁺ T cells *in vivo*.